MTR-106

• CAT Number: I038795
• CAS Number: 1639357-93-9
• Molecular Formula: C28H27N7O2S
• Molecular Weight: 525.62
• Purity: ≥95%
• Synonyms: 2-[(3aR,6aS)-2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide
• InChI: InChI=1S/C28H27N7O2S/c1-16-9-30-19(10-29-16)11-31-27(37)24-25(36)20-7-8-23(34-14-17-12-33(2)13-18(17)15-34)32-26(20)35-21-5-3-4-6-22(21)38-28(24)35/h3-10,17-18H,11-15H2,1-2H3,(H,31,37)/t17-,18+
• InChIKey: KJAFGGSRXHIQPT-HDICACEKSA-N
• SMILES: CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CC7CN(CC7C6)C

MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer[1].
MTR-106 (0-100 μM; 7 d) has antitumor activity in both HR-deficient cells and PARPi-resistant cells[1].
MTR-106 (0-100 μM; 7 d) induces apoptosis, cell cycle arrest and DNA damage[1].
MTR-106 (10-30 mg/kg; p.o.; twice a week, for 29 days) suppresses the tumor growth of BRCA-deficient and PARPi-resistant xenografts in nude mice[1].

Reference

[1]. Li MZ, et, al. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Invest New Drugs. 2021 Oct;39(5):1213-1221.
 [Content Brief]